Figures & data
Table 1 Baseline Characteristics of Patients Diagnosed with HER2 Positive Metastatic Breast Cancer from January 2013 to June 2021 That Initiated Systemic 1L Treatment (n = 61)
Table 2 Time on Treatment from First-Line and Second-Line Treatment Initiation for Patients Diagnosed with HER2 Positive Metastatic Breast Cancer with Brain Metastases Diagnosed during Their Metastatic Disease, from January 2013 to June 2021 (n = 61)
Figure 2 Time on treatment and overall survival from first-line treatment initiation for patients diagnosed with HER2 positive metastatic breast cancer with brain metastases diagnosed during their metastatic disease, from January 2013 to June 2021 (n = 61).
![Figure 2 Time on treatment and overall survival from first-line treatment initiation for patients diagnosed with HER2 positive metastatic breast cancer with brain metastases diagnosed during their metastatic disease, from January 2013 to June 2021 (n = 61).](/cms/asset/c427ba27-1d86-4111-abfa-7e03059cb8cf/dbct_a_12301050_f0002_c.jpg)
Table 3 Overall Survival from First-Line Treatment Initiation, and Overall Survival from Brain Metastases Diagnosis for Patients Diagnosed with HER2 Positive Metastatic Breast Cancer with Brain Metastases Diagnosed during Their Metastatic Disease, from January 2013 to June 2021 (n = 61)
Table 4 Overall Survival from First-Line Treatment Initiation, and Overall Survival from Brain Metastases Diagnosis, Stratified by Time of Brain Metastases Diagnosis, for Patients Diagnosed with HER2 Positive Metastatic Breast Cancer from January 2013 to June 2021 (n = 61)